2 Oct 2026, 10:01
Company Administration—
NX1NEXALIS THERAPEUTICS LTD
Announcement history available from 1 August 2025
Fromto
1 Sept 2026, 15:46
Financial ResultsMS
31 Aug 2026, 17:57
Financial ResultsMS
31 July 2026, 13:07
Quarterly ReportsMS
31 July 2026, 13:06
OtherMS
30 July 2026, 11:02
Substantial Holders—
14 July 2026, 15:13
Director Interests—
14 July 2026, 15:12
Director Interests—
14 July 2026, 15:10
Securities Administration—
14 July 2026, 15:10
Securities Administration—
14 July 2026, 15:06
Securities Administration—
6 July 2026, 11:48
Capital RaisingMS
25 June 2026, 15:52
Company Administration—
29 May 2026, 18:23
Meetings & Governance—
29 May 2026, 16:14
Presentations—
28 May 2026, 09:48
ReinstatementMS
28 May 2026, 09:48
Capital RaisingMS
26 May 2026, 10:34
Trading Halt / SuspensionMS
22 May 2026, 09:38
Trading Halt / SuspensionMS
14 May 2026, 11:33
Company Update—
13 May 2026, 13:10
Company Administration—
30 Apr 2026, 17:13
Meetings & Governance—
30 Apr 2026, 17:12
Meetings & Governance—
30 Apr 2026, 17:10
Presentations—
30 Apr 2026, 14:40
Quarterly ReportsMS
30 Apr 2026, 14:40
OtherMS
28 Apr 2026, 09:25
Company Update—
23 Apr 2026, 09:41
Company Update—
20 Apr 2026, 09:59
Company UpdateMS
17 Apr 2026, 09:50
Company Update—
31 Mar 2026, 17:59
Financial Results—
31 Mar 2026, 17:41
Company Administration—
25 Mar 2026, 14:34
Company Administration—
19 Mar 2026, 09:22
Company UpdateMS
4 Mar 2026, 11:26
Company UpdateMS
27 Feb 2026, 17:34
Financial ResultsMS
23 Feb 2026, 10:32
Securities Administration—
23 Feb 2026, 10:32
Securities Administration—
20 Feb 2026, 13:54
Securities Administration—
20 Feb 2026, 13:50
Securities Administration—
17 Feb 2026, 15:45
Securities Administration—
17 Feb 2026, 11:13
Securities Administration—
17 Feb 2026, 11:12
Securities Administration—
17 Feb 2026, 11:05
Director Interests—
17 Feb 2026, 11:00
Securities Administration—
17 Feb 2026, 11:00
Securities Administration—
17 Feb 2026, 10:44
Securities Administration—
17 Feb 2026, 10:44
Capital Raising—
| Date / Time | Heading | Type | MS | Report Codes | |
|---|---|---|---|---|---|
| 2 Oct 2026, 10:01 | Chair Appointment/Resignation | Company Administration | — | 12001, 12017 | |
| 1 Sept 2026, 15:46 | Removal of draft wording in the directors report HY accounts | Financial Results | MS | 03004, 03009, 03010, 03015, 03019 | |
| 31 Aug 2026, 17:57 | Half Yearly Report and Accounts | Financial Results | MS | 03004, 03009, 03010, 03015, 03019 | |
| 31 July 2026, 13:07 | Jun26 Appendix 4C Cash Flow Report | Quarterly Reports | MS | 19002 | |
| 31 July 2026, 13:06 | Jun26 Quarterly Activities Report | Other | MS | 19007 | |
| 30 July 2026, 11:02 | Change in substantial holding | Substantial Holders | — | 02002 | |
| 14 July 2026, 15:13 | Change of Director's Interest Notice - Sean Williams | Director Interests | — | 02009 | |
| 14 July 2026, 15:12 | Change of Director's Interest Notice - Darryl Davies | Director Interests | — | 02009 | |
| 14 July 2026, 15:10 | Notification of cessation of securities - NX1 | Securities Administration | — | 06027 | |
| 14 July 2026, 15:10 | Notification regarding unquoted securities - NX1 | Securities Administration | — | 06021 | |
| 14 July 2026, 15:06 | Issue of director share rights post shareholder approval | Securities Administration | — | 06009 | |
| 6 July 2026, 11:48 | Update on Funding Facility and Clinical Program | Capital Raising | MS | 03014, 03022, 11001 | |
| 25 June 2026, 15:52 | Director Appointment/Resignation | Company Administration | — | 02008, 02010, 12001 | |
| 29 May 2026, 18:23 | 2026 AGM results | Meetings & Governance | — | 08003 | |
| 29 May 2026, 16:14 | 2026 AGM slides | Presentations | — | 03026, 15002 | |
| 28 May 2026, 09:48 | Reinstatement to Official Quotation | Reinstatement | MS | 09002 | |
| 28 May 2026, 09:48 | Binding Letter of Intent to replace existing $53m facility | Capital Raising | MS | 03022, 06009, 11001 | |
| 26 May 2026, 10:34 | Suspension from Quotation | Trading Halt / Suspension | MS | 09001 | |
| 22 May 2026, 09:38 | Trading Halt | Trading Halt / Suspension | MS | 09007 | |
| 14 May 2026, 11:33 | Phase 1 IRX-616a Last Patient Last Dose | Company Update | — | 11001 | |
| 13 May 2026, 13:10 | Director Appointment/Resignation | Company Administration | — | 02008, 02010, 12001 | |
| 30 Apr 2026, 17:13 | 2026 AGM - Sample Proxy Form | Meetings & Governance | — | 08004 | |
| 30 Apr 2026, 17:12 | 2026 AGM - Access Letter | Meetings & Governance | — | 08001, 16002 | |
| 30 Apr 2026, 17:10 | Notice of Annual General Meeting | Presentations | — | 08001, 14014 | |
| 30 Apr 2026, 14:40 | Mar26 Appendix 4C Cash Flow Report | Quarterly Reports | MS | 19001 | |
| 30 Apr 2026, 14:40 | Mar26 Quarterly Activities Report | Other | MS | 19006 | |
| 28 Apr 2026, 09:25 | Phase 1 IRX-616a Trial Advances to Final Cohort | Company Update | — | 11001 | |
| 23 Apr 2026, 09:41 | US Policy Market Advancement Supports SRX-25 TRD Treatment | Company Update | — | 11001 | |
| 20 Apr 2026, 09:59 | Significant Milestone - First Patient Screened IRX-211 Ph2 | Company Update | MS | 11001 | |
| 17 Apr 2026, 09:50 | Phase 1 IRX-616a Trial Advances - Positive Safety Review | Company Update | — | 11001 | |
| 31 Mar 2026, 17:59 | 2025 Annual Report | Financial Results | — | 03001, 03002, 03011, 03012, 03013, 03020 | |
| 31 Mar 2026, 17:41 | 2025 Corporate Governance Statement and 4G | Company Administration | — | 03024, 03025 | |
| 25 Mar 2026, 14:34 | Nexalis to present at the NWR Virtual Healthcare Conference | Company Administration | — | 12008 | |
| 19 Mar 2026, 09:22 | First patient dosed in IRX-616a Phase 1 trial | Company Update | MS | 11001 | |
| 4 Mar 2026, 11:26 | First eligible participant screened - phase 1 IRX-616a study | Company Update | MS | 11001 | |
| 27 Feb 2026, 17:34 | Preliminary Final Report | Financial Results | MS | 03003 | |
| 23 Feb 2026, 10:32 | Cleansing Notice | Securities Administration | — | 06018 | |
| 23 Feb 2026, 10:32 | Application for quotation of securities - NX1 | Securities Administration | — | 06020 | |
| 20 Feb 2026, 13:54 | Proposed issue of securities - NX1 | Securities Administration | — | 06013 | |
| 20 Feb 2026, 13:50 | Issue of shares to satisfy Advisory/Lead Manager Services | Securities Administration | — | 06009 | |
| 17 Feb 2026, 15:45 | Cleansing Notice | Securities Administration | — | 06018 | |
| 17 Feb 2026, 11:13 | Notification regarding unquoted securities - NX1 | Securities Administration | — | 06021 | |
| 17 Feb 2026, 11:12 | Proposed issue of securities - NX1 | Securities Administration | — | 06013 | |
| 17 Feb 2026, 11:05 | Change of Director's Interest Notice x3 | Director Interests | — | 02009 | |
| 17 Feb 2026, 11:00 | Notification regarding unquoted securities - NX1 | Securities Administration | — | 06021 | |
| 17 Feb 2026, 11:00 | Notification regarding unquoted securities - NX1 | Securities Administration | — | 06021 | |
| 17 Feb 2026, 10:44 | Application for quotation of securities - NX1 | Securities Administration | — | 06020 | |
| 17 Feb 2026, 10:44 | ALLOTMENT OF SECURITIES FOLLOWING SHAREHOLDER APPROVAL | Capital Raising | — | 06003, 06009 |
1–48 of 48
1 / 1